News

Medications used alone or in conjunction with prostaglandin have substantial IOP-lowering effects

Treatment with the fixed combination of brinzolamide 1%-brimonidine 0.2% (Simbrinza, Alcon Laboratories) was associated with significantly greater IOP-lowering than either brinzolamide or brimonidine monotherapy.

Although generic medications approved by the FDA are identical to the innovator in their active and inactive ingredients, prescribers must be cognizant about sources of problems associated with the use of ophthalmic generic drugs.

The advancement of AR-13324 into phase III represents a major step toward the goal of adding an effective and well-tolerated trabecular outflow drug to the glaucoma armamentarium.

Two-year results on the first ab interno micro-stent designed to drain into the suprachoroidal space show good efficacy and safety profiles.

Glaucoma medications should be used judiciously in women of childbearing age as they may pose risks to the infants of pregnant or nursing patients.

The RETAIN Study of the effect of retinal vein occlusion (RVO) treated with ranibizumab injections found good visual acuity results in patients with branch RVO.

Collections include new frame types, colors, and various new features.

Ellex Medical Lasers Ltd. has acquired the canaloplasty business of US-based iScience Interventional Inc., which comprises the iTrack 250 catheter and suture device for the treatment of mild-moderate glaucoma.

ThromboGenics’ ocriplasmin (Jetrea) has received a positive Common Drug Review (CDR) in Canada.

Kala Pharmaceuticals Inc. has submitted an Investigational New Drug (IND) application to the FDA to initiate a phase III clinical program with its mucus-penetrating particle (MPP) technology-formulated loteprednol etabonate ophthalmic nano-suspension product (LE-MPP).

Physician claims new IOL power calculating formula gives more accurate measurements as it factors in gender-specific differences of the human eye.

Determining the optimal IOL power for children is as much an art as a science.

There are many causes of limbal stem cell deficiency and it is important to know how to recognize them and how to intervene.

Endoscopy during cataract surgery improves visualization during nearly all steps of the procedure in eyes with an opaque cornea.

Recently unveiled technology that aims at early detection and tracking of AMD can prevent vision loss and improve quality of life in patients with the disease.

In a randomly assigned study, including 487 eyes with a leaking clear corneal incision after cataract surgery, closure with a hydrogel sealant was significantly more effective than suturing for preventing fluid egress and was associated with significantly fewer adverse events.

The CRS’s assortment of technology used in cataract surgery allows interaction between devices to give better results before and after a procedure.

With femtosecond laser lens pretreatment and optimization of the surgical approach, removal of even dense cataracts (LOCS III grade 4) can now be completed without any ultrasound in nearly all cases.

: The Verion Image Guided System (Alcon Laboratories), composed of the Verion Reference Unit and the Verion Digital Marker, allows cataract surgeons to deliver better refractive outcomes.

Femtophaco surgical procedures using a femtosecond laser have resulted in much-improved cataract and corneal outcomes.

Recently unveiled device features video of intraoperative wavefront data that allows cataract surgeons to see continuous real-time refraction changes during surgery.

Study suggests that new IOL measurement technology works more effectively than previously thought, however, still rely upon aspects of existing formulae to determine the final lens power.

Photodynamic therapy has been found to reduce subretinal fluid and increase visual acuity for patients with central serous chorioretinopathy.

Study of fourier OCT to evaluate flap architectures in LASIK patients finds that both a mechanical microkeratome and a femtosecond laser create thin planar flaps.

An investigational modular IOL was designed to improve surgeons’ ability to select the right optic the first time, enable safe and easy postoperative enhancement when required, and minimize posterior capsule opacification. A multicenter clinical trial evaluating the IOL was launched in October.

Analysis finds procedure extremely cost effective; ROI has net $123.4 billion over 13 years

Steven J. Fliesler, PhD, has been chosen as an Association for Research in Vision Ophthalmology (ARVO) 2014 Gold Fellow.